CD40 and neoplasm: We also provided evidence that metabolic interventions by depleting LDHA and GLS (a key enzyme of glutaminolysis), which are two metabolic targets under investigations in clinical trials for cancer therapy, abrogated the anti-tumor response of TAMs induced by agonistic anti-CD40 antibody [148].